Author: Ben Rogers
New Research on Gut Chemical Succinate Could Change Crohn’s Treatment
New research reveals that succinate, a naturally occurring gut chemical, may drive inflammation in Crohn’s disease. This discovery could lead to targeted treatments that rebalance gut chemistry rather than broadly suppressing the immune system.
Plant-Based Eating May Lower IBD Risk – But Quality Matters
New research suggests healthy plant-based diets rich in whole foods may help protect against IBD development. However, the quality of plant foods matters more than simply avoiding animal products, with processed plant foods offering no protective benefits.
New Hope on the Horizon: IBD Treatment Options Are Expanding
Recent research shows the IBD and IBS treatment market is experiencing significant growth, driven by better diagnostics, increased awareness, and substantial investment in new therapies. This expansion could mean more personalized treatment options and improved quality of life for people living with inflammatory bowel disease.
New Hope for Kids with Crohn’s: Breakthrough Study Results
AbbVie’s new pediatric Crohn’s study shows promising results for children with moderate to severe disease who haven’t responded to other treatments. The research offers hope for fewer symptoms and better remission maintenance in young patients.
Managing Social Media During IBD Flares: Your Mental Health Matters
Struggling with whether to share your IBD journey online during flares? You’re not alone in feeling torn between staying connected and protecting your mental health. Here’s why both choices are valid and how to decide what works best for you.
Ustekinumab vs Vedolizumab: Real Hope for Better Crohn’s Control
New real-world research comparing ustekinumab and vedolizumab shows promising results for Crohn’s patients. We break down what this means for your treatment decisions and conversations with your doctor.
Palisade Bio’s Financial Update: What IBD Patients Need to Know
Palisade Bio’s latest financial report reveals steady progress in IBD treatment development, with successful fundraising supporting ongoing clinical programs. Understanding what these financial milestones mean can help patients gauge the future treatment landscape.
